OKLAHOMA CITY – Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in small batch clinical production of biologics and GMP-grade reagents using their open-source platform, Portable CMC™, today announced the first closing of their Series A financing round. The round was co-led by Charles River Laboratories and Echo Investment Capital with participation from ATUM, Floating Point Advisors, Plains Venture Partners (a subsidiary of i2E), and Pine Ridge Ventures.
Wheeler Bio announces oversubscribed Series A-1, plans for expansion and continued growth
The financing will broaden Wheeler’s capabilities, paving the way for future growth and planned build-out of a 52,000 square foot manufacturing facility.